Antibiotic resistance is an increasingly serious threat to global public health. Urgent solutions are needed to tackle the growing list of infections that have become harder, and in some cases impossible, to treat. 1
Ferring is joining the global fight against antibiotic resistance through a collaboration with Intralytix.
Together, our companies are working to identify a bacteriophage-based treatment for vancomycin resistant enterococci (VRE), multidrug resistant bacteria that have caused hospital outbreaks worldwide.2
“VRE infections occur mainly among people with weakened immune systems or long-term illnesses, as well as those recovering from surgery, who have been treated with multiple antibiotics,” explains Kristin Wannerberger, Director, Alliance Management, R&D at Ferring.
“We’re excited to be collaborating with Intralytix, a leader in the development of bacteriophage treatments, to search for a solution for these patients.”
VRE presents a major challenge in hospital and healthcare settings, and developing an effective solution to treat it is urgently needed.3
“I like to think of bacteriophages as microbial heroes - bringing down bad bacteria and eating superbugs for breakfast,” says Alexander Sulakvelidze, Executive Vice President and Chief Scientific Officer, Intralytix.
“Properly selected bacteriophages can selectively kill bad bacteria such as VRE without disturbing the normal flora bacteria that are beneficial to us. I believe that bacteriophages can become a very important tool for managing antibiotic resistant bacteria. ”